Rosana Kapeller rais­es $77M in bid to make re­peatome drugs a re­al­i­ty

Giv­en the choice, Rosana Kapeller would have picked dif­fer­ent cir­cum­stances to be a first time founder-CEO.

The long­time com­pu­ta­tion­al bi­ol­o­gist, an ear­ly vet­er­an of Mil­len­ni­um and Nim­bus, be­gan putting to­geth­er her lat­est ven­ture in late 2019, rais­ing the Se­ries A for Rome Ther­a­peu­tics in the win­ter and ear­ly spring of 2020. And then, of course, the world shut down.

Kapeller, sprite­ly but forth­right, ac­knowl­edges it’s been a strug­gle. She went a year with­out see­ing most of the team she was build­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER